(1)Resistell
Resistell Ltd is a clinical stage Swiss start-up developing the first class nanomotion technology platform consisting of hardware, software and a big data machine learning system for Antibiotic Susceptibility Testing (AST), as well as a wide spectrum of clinical and research applications in life science. Resistell’s first product, Phenotech R&D, was launched in April 2022 and is available for sales for research applications. The second product, Phenotech AST, is currently in clinical validation for bloodstream infections and sepsis where it has achieved excellent accuracy with clinical gold standard methods while providing results within 4 hours only.
(2)BigOmics
BigOmics Analytics is a Swiss data analytics startup that was founded in 2018 as a spin-off of the Institute of Oncology Research in Bellinzona. The company was started to address the current omics data analysis bottleneck that is slowing down the rate of discovery in the biological and medical sciences. As such, we create smart online tools to make advanced omics analysis accessible to users without bioinformatics skills. In the long term, we consider this an essential step in fulfilling the promises of personalised medicine.
We launched our first product, Omics Playground, a cloud-based self-service platform for visual data analytics of omics data. So far, we have raised CHF 2.7M in funding. Our platform is currently being used by three biotech and pharma clients, as well as five academic institutions across the world.
(3)Arkaïya
Arkaiya™ unique gatekeeping Archaea companion diagnostic and accompanying therapeutic agent are the much needed and ‘underlying-problem-addressing’ solution made available to doctors and parents for the treatment of their distressed infants and young children, suffering from colic, asthma, allergies and associated acute and chronic inflammatory and autoimmune conditions, commonly caused by the early absence or shortage of gatekeeping Archaea M. smithii in the child’s gut microbiome, due to premature or Caesarean birth, formula (non-breast) feeding or early exposure to antibiotics.
Arkaiya™ combined diagnostic and therapeutic solution promises to dramatically improve the early and later ‘microbiome-balanced and optimized‘ lives of infants suffering from these troubling and potentially chronic problems, substantially reducing life-long allergy and GI-related doctor and hospital visits and morbidity and healthcare costs.
(4)Pipra
Delirium is one of the largest issues in healthcare and is massively unaddressed, affecting 59 million people per year. It represents a significantly higher cost than diabetes (60% higher cost in the U.S.). Post-Operative Delirium (POD) is the most common post-surgical complication affecting 20% of patients over 60 with long-term consequences for patients and enormous costs to hospitals and insurers. 38% of patients with POD continue to experience cognitive decline 9 months post-surgery. Our first product is a CE-certified, A.I-driven clinical decision support software that helps doctors identify high-risk patients prior to surgery. Highlighting high-risk patients allows for effective, cost-reducing measures to be implemented shown to decrease the incidence by 53%. We recently launched our product on the market in Switzerland have secured 3 paid pilots with well-known and respected hospitals. We are strongly supported by several key opinion leaders on our advisory board (i.e. from Johns Hopkins, Harvard, Cornell).
(5)Synplechem
Synple Chem, an ETH spin-off, has developed an automated reagent cartridge-based syntheszier for the safe and efficient assembly of new molecules.
The synthesizer works in analogy to a well-known coffee capsule system, carrying out chemical synthesis at the touch of a button. Using our device, researchers can synthesize new molecules in a manner that is much faster, cheaper, safer, and more efficient than traditional manual methods. By offering a broad range of cartridges capable of effecting the most frequently used chemical reactions in the pharmaceutical industry, Synple Chem’s technology platform has the potential to speed up drug discovery and bring new medicines to the patient faster.
(6)Netsensing Technology
Founded in 2019 in Switzerland, Netsensing Technology is developing a low-cost device to enable the mass detection of sleep apnea, that drastically reduces time and cost of detection, easy to use without wires and tubes, fully reimbursable, AASM and telemedicine compliant. More, it will be placed at pharmacies for immediate access by patients. Technically, Netsensing will use, AASM compliant sensors and software, all integrate in a lowcost wearable and stretchable device that looks like a corset.
(7)Kralys
Kralys is a Swiss medtech startup founded in 2017 in Montreux. It offers solutions for practitioners, therapists and labs in Switzerland and has just started its internationalization plan, notably Japan and France. Kralys’ mission is to ensure that everyone has access to the best digital health solutions, everywhere. Designed with healthcare professionals for healthcare professionals. The company has so far developed three distinct solutions with some of the most prestigious laboratories and professionals in Switzerland:
· Katarina for doctors: An all-in-one software suite to manage the medical practice and clinic from A to Z.
· Laboratory Order Entry: A digital platform that connects the laboratory with its customers and enables the ordering and tracking of complex laboratory analyses, supporting pre-analytical procedures and label customization.
· Lab. Connector: A wireless controller that translates and transmits all your medical data, to all your devices, in the cloud.
(8)Cytosurge
Cytosurge expanded its business from a pure nanotech solution provider to a service provider for CRISPR cell line engineering in spring 2022. Our world’s smallest syringe injects femto- to nanoliter amounts of CRISPR reagents directly into the nucleus of individual cells and allows expansion of monoclonal cell lines accordingly. Compared to standard methods, we avoid single cell selection from millions of cells and are therefore able to provide a significantly faster service speed at unprecedented quality, even for complex cell edits. Hence, by applying disruptive and fully digitalized manufacturing services based on our unique technology, we go beyond conventional technological boundaries in gene editing. We are looking for investments to further scale up our cell line business and to further automate our cell culturing and expansion processes.
(9)MachineMD
machineMD is a Swiss medical device company, founded in 2019, that develops innovative solutions to radically improve early detection of brain disorders such as stroke, multiple sclerosis and brain tumours. The company was founded in Prof. Mathias Abegg’s Eye Movement Laboratory in the University Hospital of Bern. Together they combine Virtual Reality and Artificial Intelligence to empower neurologists and ophthalmologists with reliable diagnostic data.
NEOS is the neurophthalmoscope for standardized and automated examinations of neurological disorders via the visual pathway. Medical examination time is reduced from 45 to 10 minutes, bringing the quality of a highly trained tertiary care specialist to where it is most needed, in secondary and primary care.
The device is intended to provide objective, reproducible and quantifiable measurements of eye and pupil movements induced by visual stimuli. Eight neuro-ophthalmic examinations are performed, including pupillary function and visual field measurements.
NEOS is currently for Research Use Only and is not yet available in any market.
